381 results about "Humanized antibody" patented technology

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.

The invention provides an antibody specifically combined with CDH6 (cadherin 6) and application thereof, and particularly discloses mouse and humanized antibodies combined with CDH6 as well as a preparation method and application thereof, and the mouse and humanized antibodies have better affinity with CDH6 protein and better endocytosis activity, so that the mouse and humanized antibodies can be applied to preparation of medicines for treating tumors and the like.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The present invention addresses the problem of producing a novel anti-CDH3 humanized antibody and providing, by using the antibody, an (anti-CDH3 humanized antibody)-drug conjugate capable of more efficiently killing CDH3-expressing cancer cells. According to the present invention, either of the following antibodies is provided. (1) An anti-CDH3 humanized antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2; or (2) an anti-CDH3 humanized antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4.

The invention provides a B7H7 targeting antibody or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 1-5 or an amino acid sequence with at least 80% of identity with the amino acid sequence as shown in SEQ ID NO: 1-5; the light chain variable region CDR sequence has an amino acid sequence as shown in SEQ ID NO: 6-8 or an amino acid sequence with at least 80% identity with the amino acid sequence as shown in SEQ ID NO: 6-8. The mouse antibody and the humanized antibody prepared by the invention can be specifically combined with B7H7 in a targeting manner, block the combination of B7H7 and a receptor KIR3DL3 thereof, and promote the killing of immune cells on tumor cells, so that B7H7-mediated related diseases are effectively treated or prevented.

The present invention relates to monoclonal humanized antibodies or antigen-binding fragments thereof that specifically bind to the TRBV9 family of human T-cell receptors. The present invention also relates to nucleic acids encoding said antibodies or antigen-binding fragments thereof, expression vectors, methods for preparing said antibodies and the use of said antibodies in the treatment of diseases or disorders associated with said family of human T-cell receptors. The present invention relates to the production of antibodies that can be used to treat, inter alia, ankylosing spondylitis (AS or Bechterev's disease), celiac disease and blood cancers, whose pathogenesis involves T-cell receptors of the TRBV9 family.

Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and / or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and / or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The present disclosure relates to an anti-Claudin 18.2 antibody and an application thereof. Specifically, the present invention relates to an anti-Claudin 18.2 antibody; a mouse-derived antibody, chimeric antibody, humanized antibody and antigen-binding fragment thereof which contain a CDR of the anti-Claudin 18.2 antibody, and a use thereof as a medicine. In particular, the present disclosure relates to a use of the anti-Claudin 18.2 antibody in the preparation of a drug for treating Claudin 18.2 positive diseases or disorders.

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.

The invention relates to a polypeptide Nb3-26 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-26 is constructed; meanwhile, the curative effect of the Nb3-26 on treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention provides a preparation method and application of a genetically modified non-human mammal for producing a humanized antibody. The preparation method comprises the following steps: (1) destroying an endogenous heavy chain immune globulin locus of a non-human mammal; and (2) introducing a human IGHV gene, a human IGHD gene, a human IGHJ gene, and an endogenous IgHG gene, an endogenous IgHE gene, an endogenous IgHA gene and an endogenous LCR region of the non-human mammal into the non-human mammal obtained in the step (1). The non-human mammal prepared by the preparation method disclosed by the invention can efficiently generate a humanized complete antibody or a single-chain antibody or a nano antibody after being immunized by an antigen, and has relatively high immune titer, and moreover, the preparation method disclosed by the invention can be used for obtaining a positive animal with relatively high efficiency, so that the non-human mammal can be used for preparing the non-human mammal. Therefore, humanized mice with different antibody diversity can be easily prepared, and the nanometer antibody sequence diversity can be realized by using various strains of mice.

A method for treating or preventing GvHD in a human patient, comprising administering to a patient suffering from GvHD or at risk for GvHD, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has or is going to have an allogeneic stem cell transplantation, and wherein the dosing regimen prevents, improves or eliminates GvHD.

The invention relates to a VHH nano antibody Nb3-17 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-17 is constructed; meanwhile, the curative effect of Nb3-17 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The present invention relates to antibody-drug conjugates (ADCs) that target the receptor uPARAP, and in particular to antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP, and their use in delivering active agents to cells and tissues expressing exatecan derivatives and uPARAP. The present invention further relates to the use of the ADCs in the treatment of diseases involving uPARAP-expressing cells, such as certain cancers.

The invention belongs to the technical field of biological medicines, and particularly relates to a humanized monoclonal antibody h3D8 for inhibiting HTNV infection and application of the humanized monoclonal antibody h3D8. The humanized monoclonal antibody h3D8 comprises a heavy chain and a light chain; the amino acid sequence of the heavy chain is as shown in SEQ ID NO. 1; the amino acid sequence of the light chain is as shown in SEQ ID NO. 2. The invention provides a humanized anti-HTNV virus infection antibody h3D8. The antibody is combined with a virus to block the combination of the virus and a cell receptor so as to avoid infection of a host. The h3D8 antibody provided by the invention is a safe and effective anti-HTNV humanized antibody, has huge application potential, is expected to enter a clinical test to evaluate the antibody drug, and has huge application transformation potential.

The present invention relates to humanized antibodies or target-binding fragments or derivatives thereof retaining target binding capacities, which bind to human iRhom2 (FIG. 1).

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The present invention provides a GD2-targeting CAR-T cell and its preparation and application. Specifically, the present invention provides a GD2-targeting CAR construct, which comprises the scFv fragment of the humanized GD2 antibody 3F8, the human Fc fragment, the ICOS transmembrane region, the ICOS and 4-1BB intracellular regions (co-stimulatory signals), and CD3ζ. The present invention also provides a CAR-T cell based on the above CAR, its preparation method and application. The CAR-T cell of the present invention can significantly inhibit the proliferation of tumor cells in a subcutaneous model of neuroblastoma, has a significant in vivo anti-tumor effect, and can be used for the targeted treatment of neuroblastoma.

A Claudin18.2 humanized antibody and application thereof. The antibody contains a chain variable region (CDR) sequence selected from at least one of the following or an amino acid sequence having at least 90% identity therewith: light chain CDR sequences: SEQ ID NOs: 1-3 and 7-9; and heavy chain CDR sequences: SEQ ID NOs: 4-6 and 10-12; The antibody or an antigen-binding fragment thereof have humanized modification. The humanized antibody can specifically target and bind Claudin18.2, has the same in vitro activity as a human-mouse chimeric anti-Claudin18.2 monoclonal antibody, meets the requirements of druggability, and has significantly prolonged in vivo half-life.

The present invention relates to the field of biomedicine, and more specifically, to a humanized anti-human PD-L1 antibody or antigen-binding fragment thereof and its use. The antibody or antigen-binding fragment thereof of the present invention has high affinity and strong binding specificity for PD-L1, effectively blocks the binding of PD-L1 to PD-1 and CD80, stimulates cytokine production, and exhibits significant anti-tumor effects. It can be used alone or in combination with other agents to prevent or treat immune disorders or tumor-related diseases.

The present invention provides humanized antibodies targeting CD7, as well as multispecific antibodies, chimeric antigen receptors, antibody conjugates, pharmaceutical compositions and kits comprising the same, and their use in the diagnosis / treatment / prevention of diseases associated with CD7 expression.

Humanized monoclonal anti-nuclear antibodies with enhanced binding affinity and tumor uptake are presented. Particularly preferred antibodies are site-directed mutants of H-CDR3 with up to about 8-fold improvement in affinity as compared to the non-humanized non-mutated form. In further preferred aspects, such humanized antibodies are employed in tumor necrosis targeted delivery of immune modulators, immune effectors, and other therapeutic or diagnostic agents.

Novel binding molecules comprising humanized antibodies, fragments, variants, and derivatives thereof, as well as compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FX1 and FX1a. The binding molecules are capable of binding to the factor X1A2 domain and forming immune complexes, thereby disrupting the contact activation molecule complex without affecting the activity or activation of hemostatic factor XI. The binding molecules disclosed herein are suitable for safely inhibiting thrombosis and inflammation without impairing hemostasis. Thus, the binding molecules, compositions, methods, and kits provided herein are intended for treating diseases and conditions, particularly those associated with thrombosis and inflammation. In addition, polynucleotides encoding the binding molecules disclosed herein, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are also provided.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

Relates to anti-5T4 antibodies, in particular humanized antibodies. The invention also relates to pharmaceutical compositions comprising these antibodies and pharmaceutical uses thereof. The antibody has relatively high affinity, relatively good cell binding force and relatively high internalization rate, and can be used for treating 5T4 overexpression diseases, such as cancers.